Troy– Author –
-
PitchBook Analysis: Rebounding Biotech Funding Expected to Drive CDMO Growth in 2026, Focus on Complex Modalities
BioSpace USA Overview This article provides an overview of a PitchBook analysis report. According to PitchBook, biotech venture capital funding in the first half of 2026 surpassed $10 billion, driven significantly by Isomorphic Labs' $2.... -
Biotech VC Funding Reaches $20.1 Billion in H1 2026 as Companies Secure Significant Capital for Early Development Stages
BioBucks / Fierce Biotech USA Overview In the first half of 2026, biotech VC funding totaled $20.1 billion, with several companies completing major financing rounds. Vaderis Therapeutics secured $152 million in Series B for a Phase III t... -
K-38 Consulting Report: Biotech VC Funding Rebounds to Over $9.1 Billion in H1 2026, While Early-Stage Investment Hits Pre-Pandemic Low
WBOC (Press Release) USA Overview This article presents an overview of a market research report by K-38 Consulting. The report indicates that biotech venture capital funding in the first half of 2026 exceeded $9.1 billion, reaching its h... -
DCAT Report: 2026 CDMO Market Sees Major M&A and Capital Investments, with Samsung Biologics to Acquire PolyPeptide Group for $1.8 Billion
DCAT Value Chain Insights USA Overview According to a DCAT Value Chain Insights report, the 2026 CDMO market is witnessing a surge in peptide-based drug development, accompanied by significant M&A and capital investments. Samsung Bio... -
Keymed Biosciences’ BCMA x CD3 Bispecific Antibody CM336 Advances to Phase II for Relapsed/Refractory Light Chain Amyloidosis, Secures $257M from Gilead’s Acquisition of Partner
BioSpace China Overview Keymed Biosciences announced its H1 2026 results and business updates, reporting that its BCMA x CD3 bispecific antibody, CM336, is progressing in a Phase II clinical trial for relapsed/refractory light chain amyl... -
FDA Grants Breakthrough Therapy and Fast Track Designations to Norroy Bioscience’s 68Ga-NYM096 for Clear Cell Renal Cell Carcinoma PET Imaging, First Chinese-Origin Radiopharmaceutical to Receive BTD
Targeted Oncology USA Overview The U.S. FDA has granted Breakthrough Therapy Designation (BTD) and Fast Track Designation (FTD) to Norroy Bioscience's investigational PET imaging agent, 68Ga-NYM096, for detecting clear cell renal cell ca... -
FDA Approves Novo Nordisk’s Pasatru for FOP, Accelerates Approval for Tudriqev Combination in Melanoma, and Greenlights mFLUSIVA mRNA Flu Vaccine
Drugs.com USA Overview In August 2026, the FDA approved several key new drugs. Novo Nordisk's Pasatru (garetosmab-grts) gained approval for adults with Fibrodysplasia Ossificans Progressiva (FOP). An accelerated approval was granted for ... -
Serina Therapeutics Highlights POZ Platform’s Potential to Enhance Efficacy and Safety of Small Molecule, RNA, and ADC Therapies
BioSpace USA Overview Serina Therapeutics announced its Q2 2026 financial and business updates, emphasizing the advancement of its wholly-owned pipeline for neurological and other indications, powered by its proprietary POZ Platform™. Th... -
Johns Hopkins Medicine Unveils Synthetic mRNA Platform for Faster, More Efficient Next-Gen Therapeutics
Johns Hopkins Medicine USA Overview Scientists at Johns Hopkins Medicine have announced the development of an experimental synthetic mRNA-based platform that holds the potential to deliver next-generation mRNA therapeutics for infectious... -
Unicorn Bioscience Report: Exosome Therapy Market Valued at $58.1 Billion Despite No FDA Approvals, 240 Clinical Trials Underway
Unicorn Bioscience Unknown Overview This article provides an overview of a market research report published by Unicorn Bioscience. As of 2026, the global therapeutic exosome market is valued at $58.1 billion, a paradoxical valuation give...
